Research indicates that the combined application of ATR inhibitors and DNA damage inducers triggers synthetic lethal effects, significantly enhancing the antitumor activity of chemotherapeutic agents such as cisplatin and the PARPi veliparib [71], the highly selective ATR inhibitor Berzosertib has demonstrated efficacy in suppressing pancreatic tumor progression while exhibiting minimal off‐target toxicity in normal tissues. Here, ATR is linked to pancreatic neoplasm.